Lung Transplantation in Patients With Systemic Scleroderma—Description of the First Consecutive Cases in Poland: Case Series Report and a Short Literature Review

•Pulmonary complications of systemic scleroderma are responsible for up to 60% of patients’ deaths.•For many years, most centers considered systemic scleroderma a contraindication to lung transplantation.•We proved that lung transplantation in this group of patients is possible with acceptable 1-year results.•More studies addressing the issue of lung transplantation in patients with systemic scleroderma are needed to establish more precise eligibility criteria for transplantation. Pulmonary complications of systemic scleroderma (SSc), such as interstitial lung disease and pulmonary hypertension (PH), are responsible for up to 60% of deaths among patients. For many years, most centers considered SSc a contraindication to lung transplantation (LTx); however, recent publications show that appropriately selected SSc candidates for LTx give results comparable to patients with idiopathic PH or idiopathic pulmonary fibrosis. This paper presents the cases of a 60-year-old male patient (patient 1) and a 42-year-old female patient (patient 2) diagnosed with SSc in 2019 and 2013, respectively. In both patients, interstitial-fibrotic changes in the lungs leading to respiratory failure were confirmed by high-resolution computed tomography as well as pulmonary hypertension (WHO group 3), which was also diagnosed during right heart catheterization. In both cases, despite pharmacotherapy, pulmonary fibrosis progressed, leading to severe respiratory failure. The patients were referred for LTx qualification. LTx was possible to consider in patients due to the lack of significant changes in other internal organs. Double LTx was successfully performed in both patients (patient 1—July 19, 2022; patient 2—September 14, 2022). They were discharged from the hospital in good condition on the 22nd and 20th postoperative day, respectively. LTx is a last-chance therapy that saves lives among patients with extreme respiratory failure in the course of SSc. It prolongs and improves the quality of life. The selection of appropriate patients is key to the success of the procedure.